Hsbc Holdings PLC Makes New Investment in Insulet Corporation $PODD

Hsbc Holdings PLC acquired a new stake in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 165,958 shares of the medical instruments supplier’s stock, valued at approximately $25,341,000. Hsbc Holdings PLC owned approximately 0.24% of Insulet as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PODD. Primecap Management Co. CA purchased a new position in shares of Insulet in the second quarter valued at $15,120,000. Canada Pension Plan Investment Board purchased a new stake in Insulet during the 2nd quarter worth $28,369,000. Parkman Healthcare Partners LLC purchased a new stake in Insulet during the 2nd quarter worth $20,002,000. Legal & General Group Plc purchased a new stake in Insulet during the 2nd quarter worth $47,419,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Insulet in the 2nd quarter worth $6,085,000.

Insulet Stock Performance

Shares of Insulet stock opened at $143.41 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88. The firm’s 50-day simple moving average is $154.47 and its 200-day simple moving average is $181.40. The firm has a market cap of $9.95 billion, a PE ratio of 26.81, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period last year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on PODD shares. Royal Bank Of Canada lowered their target price on Insulet from $245.00 to $160.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Leerink Partners cut Insulet from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $247.00 to $145.00 in a research note on Thursday, August 6th. William Blair began coverage on Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating for the company. Truist Financial restated a “hold” rating and set a $153.00 price objective (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Finally, BTIG Research downgraded Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $195.40.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.36% of the stock is currently owned by corporate insiders.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
• Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.